PDUFA Date
PDUFA Date: vepdegestrant
- Company
- ARVINAS, INC. (ARVN)
- Drug
- vepdegestrant
- Indication
- 1 INDICATIONS AND USAGE VEPPANU is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1) -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. VEPPANU is a heterobifunctional protein degrader indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal gr
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.